AXON ENTERPRISE, INC. quarterly report, Q1 FY2023

Axon Enterprise, Inc. — Q1 2023 Form 10-Q Summary

Business context and reporting period

Axon provides law-enforcement technology, including TASER devices, body-worn and in-car cameras, digital evidence management, cloud software, training, and related services. The filing covers the unaudited three months ended March 31, 2023, compared primarily with the three months ended March 31, 2022.

Key financial metrics

Metric	Q1 2023	Q1 2022	Change
Net sales	$343.0 million	$256.4 million	+33.8%
Product sales	$219.4 million	$176.2 million	+24.5%
Service sales	$123.7 million	$80.2 million	+54.1%
Gross margin	$204.1 million; 59.5%	$155.7 million; 60.7%	Margin down 120 basis points
Income from operations	$16.6 million; 4.8%	$17.2 million; 6.7%	Down $0.6 million
Net income	$45.1 million; 13.2%	$54.9 million; 21.4%	Down 17.7%
Diluted EPS	$0.61	$0.76	Down $0.15
Adjusted EBITDA	$65.1 million	$48.9 million	Up $16.2 million
Operating cash flow	$(56.3) million	$44.0 million	Down $100.3 million

Revenue from Software and Sensors increased 46.9% to $208.8 million, representing 60.9% of total sales. TASER segment revenue increased 17.4% to $134.3 million. Axon Evidence and cloud services revenue totaled $125.5 million, up from $83.0 million.

Net income included a $15.6 million unrealized gain on the company’s Cellebrite investment. The prior-year period included $70.4 million of unrealized gains on strategic investments and related warrants and a $14.6 million unrealized loss on Cellebrite, making year-over-year earnings comparisons less representative of underlying operating performance.

Cash flow, balance sheet, debt, and liquidity

Cash and cash equivalents were $263.4 million at March 31, 2023, compared with $353.7 million at December 31, 2022.
Cash, cash equivalents, marketable securities, and short-term investments totaled approximately $1.09 billion, excluding strategic investments and long-term investments.
Operating cash flow was negative $56.3 million, primarily reflecting increases in receivables and contract assets, prepaid and other assets, inventory, and the timing of bonus and other liability payments.
Investing cash outflow was $72.7 million, including net purchases of available-for-sale investments and $8.5 million of property and equipment purchases.
The company had $690.0 million principal amount of 0.50% convertible senior notes due 2027, carried net at $674.7 million.
No borrowings were outstanding under the $200.0 million revolving credit facility. After $7.0 million of letters of credit, $193.0 million remained available, excluding the accordion feature.
The reported credit-agreement net leverage ratio was 0.78 to 1.00, compared with a maximum permitted ratio of 3.50 to 1.00.
Management believes available funding will satisfy currently anticipated cash requirements for at least the next twelve months.

Material changes versus the prior comparable period

Revenue growth was led by cloud services, increased users and devices on the Axon network, Axon Fleet systems, and higher TASER cartridge and device sales.
Gross margin percentage declined because of nonrecurring inventory reserves and other cost adjustments, unfavorable Software and Sensors hardware mix, and lower TASER segment margins. Software and Sensors service margins improved due to professional-services performance and lower cloud-hosting costs.
Operating expenses increased 35.3% to $187.5 million. SG&A increased with headcount, wages, sales and marketing activity, commissions, stock-based compensation, and payroll taxes related to equity award vesting and option exercises. R&D increased 46.5% to $70.9 million.
Net income declined despite higher revenue because operating expenses increased and investment-related income was substantially lower than in Q1 2022.
Cash generation deteriorated sharply, with working-capital investment and investment purchases more than offsetting net income and noncash expenses.
Remaining performance obligations were approximately $4.8 billion at March 31, 2023. The company expects to recognize 15% to 25% over the next twelve months and generally the remainder over the following ten years, subject to deployment, appropriation, and cancellation risks.

Guidance, outlook, commentary, and unusual items

Management reported a projected full-year 2023 effective tax rate of 22.8% before discrete adjustments. The Q1 effective tax rate was negative 7.8%, including a $13.0 million discrete tax benefit primarily related to equity award vesting and stock option exercises.
Management highlighted continued demand for Software and Sensors products, Axon Fleet, cloud services, and the newly shipped TASER 10.
The company issued 154,500 shares through its at-the-market program, generating $33.7 million of net proceeds. Approximately 2.3 million shares remained available under the program at quarter-end.
Stock-based compensation expense was $34.4 million in Q1 2023, compared with $25.1 million in Q1 2022. The filing also describes substantial performance-based awards and potential future dilution.
Axon’s disclosure controls and procedures were not effective as of March 31, 2023 because a material weakness in revenue recognition and deferred-revenue controls remained unremediated. The weakness relates to ERP and quote-to-cash implementation deficiencies, manual processes, and invoicing errors.
The company was defending four product-liability lawsuits involving alleged wrongful death or personal injury. Management did not consider the matters probable of having a material financial effect, while noting litigation outcomes remain uncertain.
The FTC administrative enforcement action concerning Axon’s 2018 Vievu acquisition remained pending. The company disclosed that the U.S. Supreme Court’s April 17, 2023 decision favored Axon on jurisdictional challenges and remanded the matter for further proceedings on the merits.
Outstanding off-balance-sheet commitments included $7.0 million of letters of credit and $14.0 million of surety bonds.

Risks and contingencies

Government customers may delay, cancel, or not renew contracts because of appropriations, budgetary constraints, political conditions, or termination clauses.
Subscription billing can delay cash collections and increase exposure to customer credit losses; accounts receivable and contract assets totaled approximately $596.8 million net at quarter-end.
Supply-chain constraints, single-source components, inflation, freight costs, and limited TASER 10 sourcing flexibility may pressure revenue and margins.
Cybersecurity breaches, cloud outages, data loss, privacy regulation, or defects could result in customer attrition, litigation, penalties, and remediation costs.
TASER 10 is regulated as a firearm under the U.S. Gun Control Act, creating additional licensing, compliance, import, and state-law risks.
The convertible notes, warrants, and equity compensation plans may create dilution, cash requirements, and counterparty risks.
Investment gains and losses, foreign exchange, interest rates, tax examinations, and changes in the effective tax rate may materially affect reported earnings.

Important facts investors should verify

Progress and testing results for remediation of the material weakness in revenue recognition and deferred revenue.
Conversion, maturity, and potential dilution terms of the $690.0 million convertible notes, including the 2027 warrants and note hedge.
Whether the $4.8 billion remaining performance obligation balance converts to revenue and cash as expected, given government appropriation and cancellation provisions.
Sustainability of operating cash flow after the Q1 working-capital outflow and the company’s ability to fund growth without additional equity or debt.
Underlying operating performance excluding unrealized investment gains, discrete tax benefits, and elevated stock-based compensation.
Developments in the FTC litigation, product-liability cases, TASER 10 regulatory compliance, and any related financial exposure.